3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Neuroblastoma
3
Ovarian Neoplasms
2
Medulloblastoma
2
Lymphoma, B-Cell
2
Solid Tumor
1
Rhabdoid Tumor
1
Recurrence
1
Pyloric Stenosis, Hypertrophic
1
Pinealoma
1
Ovarian Germ Cell Cancer
1
Neuroectodermal Tumors, Primitive
1
Nervous System Neoplasms
1
Neoplasms, Germ Cell and Embryonal
1
Lymphoproliferative Disorders
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Glioma
1
Ganglioneuroblastoma
1
Ependymoma
1
Diffuse Intrinsic Pontine Glioma
1
Central Nervous System Neoplasms
1
Brain Neoplasms
1
Brain Diseases
1
Interventions
Injections
6
Fluorodeoxyglucose F18
4
Cyclophosphamide
4
Bevacizumab
4
toripalimab
3
fludarabine
2
Specimen Handling
2
Nivolumab
2
zimberelimab
1
tumor-cells apoptosis factor, human
1
trametinib
1
tislelizumab
1
temsirolimus
1
spartalizumab
1
pembrolizumab
1
pazopanib
1
palbociclib
1
olaparib
1
lenvatinib
1
etoposide phosphate
1
enzalutamide
1
envafolimab
1
donafenib
1
disitamab vedotin
1
dabrafenib
1
cemiplimab
1
avelumab
1
atezolizumab
1
anlotinib
1
WW Domain-Containing Oxidoreductase
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Solid Tumor
×
etoposide phosphate
×
Clear all
NCT04469530
2026-02-27
AflacST1903
Emory University
Phase 2
Recruiting
55 enrolled